Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. - Wikidata - awgldk - TriplyDB

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.

http://www.wikidata.org/entity/Q34725141

about

Bortezomib for the treatment of mantle cell lymphoma: an update The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?Management of mantle cell lymphoma in the elderly patient Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents Mantle cell lymphoma: observation to transplantation Current and emerging therapies in mantle cell lymphoma.Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Databa In chordoma, metastasis, recurrences, Ki-67 index, and a matrix-poor phenotype are associated with patients' shorter overall survival.Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study Notch-1 and Ki-67 receptor as predictors for the recurrence and prognosis of Kimura's disease.Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting.Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma Endoscopic features and prognoses of mantle cell lymphoma with gastrointestinal involvement Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.Clinical and laboratory characteristics of systemic anaplastic large cell lymphoma in Chinese patients The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.Non-Hodgkin's lymphomas, version 4.2014.Prognostic relevance of the Ki-67 proliferation index in patients with mantle cell lymphoma.Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results.Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial What is the role of 18F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?Molecular outcome prediction in mantle cell lymphoma.Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma.Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients?New developments in the pathology of malignant lymphoma: a review of the literature published from January to April 2008.Mantle cell lymphoma: state-of-the-art management and future perspective.Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?Advances in the molecular morphology of hematopathology.Temsirolimus for the treatment of mantle cell lymphoma.Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network.Lenalidomide in lymphomas and chronic lymphocytic leukemia.Indolent mantle cell lymphoma.Management of mantle cell lymphoma in the elderly: current and potential strategies.Current regimens and novel agents for mantle cell lymphoma.The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.

P2860

Q26738940-C71F2CFE-C1AF-42AE-B183-9B1129DF808C Q26772907-91616E91-ADE9-4A06-9FB4-2D2CB29C219B Q26999395-0ED48E34-D516-4D3A-822F-5A3FA244BC9E Q28075606-0FC0B858-2AD8-45AB-A4A3-622216AC605F Q28256317-BE05F55D-79CC-4493-A5D9-7CD56F515ACA Q30456545-D8350600-8D64-4DA0-8576-5B531C592606 Q30649483-34FD85A9-D458-416E-BE33-F9AD3A7321DB Q33275755-33AC8811-07D6-42BF-8EB0-48F53DC2F3F5 Q33388563-C8461B93-5585-4C91-A3B9-A559D542CFF9 Q33394873-23D82E85-D4D7-426A-90B7-D992E7BE2205 Q33572807-4164951E-CD61-402F-B1A2-FE0CC6B4C896 Q33802961-2FF8FF83-38D5-4D61-87C5-B1035ACE577D Q34037828-293851C1-F065-4EB6-81BA-CB09C3D1959E Q34095625-30427E6A-3029-463C-A4A9-864320BC2F49 Q34135450-110B3683-A524-413E-869D-F0C0CA68F650 Q34183167-DAD9E9A2-BB90-4754-86F6-A3792788EA59 Q34594224-D18E2194-3767-49E7-AE0E-F524B620B8C0 Q35111804-F9CD67A0-669F-4518-BE61-CE45498D65E5 Q35285011-7E20D87E-9B26-496E-8EC1-79B23818A20D Q36162589-D41CCFF6-5EAE-40E1-AD09-DD7235052DEF Q36216258-9EF94135-76B0-4D09-B312-DEAE5A54EBAD Q36820885-D8456EF3-4A16-40D8-85DB-B91D27F2B20F Q37062711-E75298EB-9873-4A96-8219-3401C0197747 Q37195045-BB2C1214-E754-4F74-8363-8F36886B2344 Q37269566-D205B6EA-6A12-4148-9266-7FA1FD982981 Q37271814-1BFBA062-301E-449E-BC22-C1824154E205 Q37401338-8C48D586-818D-4EC6-A7A0-B40FF9F4A29B Q37482527-5376F188-54F4-451C-9E07-1B51509E6FE2 Q37534534-D68DD57C-7911-409D-908E-34841C09FAD0 Q37577541-BC247C07-2630-4281-A401-0DA6A61BA4E1 Q37622873-3D79EBAF-C374-4EB1-A2A2-73A39434C037 Q37728866-F8EA6D4C-E1A8-431D-B6F7-CF2EE2F69CA5 Q37756388-858D5B0F-AE85-4E75-89D7-3DDB261BC833 Q37810084-8D1C90C8-9BEB-42E2-B2D1-AB2EDBA04F4E Q38047385-265FF006-6108-4E26-B145-FC2C133FEE3E Q38077277-1A7E596C-5276-4734-AEA1-A046E27BA6FE Q38127446-206F7F8F-F0CC-4635-B1E4-583D94B70E98 Q38157682-9EFB6134-A9CC-4B6D-B09B-806D9BCC6F16 Q38224186-84398B9D-BB33-47EA-8F3A-5CFFE8B1DC9A Q38230693-657AAA36-918F-4591-8ED5-5CCAA5B52BE3

P2860

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.

http://www.wikidata.org/entity/Q34725141

description

2007 nî lūn-bûn

@nan

2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Ki-67 predicts outcome in adva ...... ow Grade Lymphoma Study Group.

@ast

Ki-67 predicts outcome in adva ...... ow Grade Lymphoma Study Group.

@en

Ki-67 predicts outcome in adva ...... ow Grade Lymphoma Study Group.

@nl

type

label

Ki-67 predicts outcome in adva ...... ow Grade Lymphoma Study Group.

@ast

Ki-67 predicts outcome in adva ...... ow Grade Lymphoma Study Group.

@en

Ki-67 predicts outcome in adva ...... ow Grade Lymphoma Study Group.

@nl

prefLabel

Ki-67 predicts outcome in adva ...... ow Grade Lymphoma Study Group.

@ast

Ki-67 predicts outcome in adva ...... ow Grade Lymphoma Study Group.

@en

Ki-67 predicts outcome in adva ...... ow Grade Lymphoma Study Group.

@nl

P1433

Q34725141-F06C3199-9DFD-4A20-9BAE-8B1F4E872012

P1476

Q34725141-07AED473-80F2-463D-BA81-B59A6411DC4F

P2093

Q34725141-04F4F242-9BB5-4A96-A4F7-46508D4A07C0

Q34725141-070E2F9D-F147-4449-9E59-DA0A1A69F183

Q34725141-105D4362-D22A-4E88-84A3-72328AFD9B41

Q34725141-220C530D-DCA3-456C-92C0-7A55CA0D1365

Q34725141-277396ED-ACD4-4170-8A5D-2B1F58D8B0E8

Q34725141-3F834130-DE89-4AA7-94E5-D4C15CA50314

Q34725141-47B2AD54-22FB-413D-B1F2-A6CCBDE34DB2

Q34725141-67A5F6C0-5C14-418D-A307-EE008B718CDF

Q34725141-A7BEA462-D7CC-4AA9-BA54-552A48F4B11A

Q34725141-AE32D463-5989-4625-9239-F9154E46EC1F

P304

Q34725141-DBE362B1-2796-474A-8785-4E67D4A1DB7F

P31

Q34725141-342E5193-634A-4579-A80F-07CBFEDBC596

P356

Q34725141-E4F40485-F3BA-4625-B807-729D2F616A57

P407

Q34725141-973E2A69-587A-431C-82AF-92559B7FE249

P433

Q34725141-EF4386E0-AF52-403A-AECC-B2E6E06B0681

P478

Q34725141-635ED076-1CB4-4A9B-8867-A8D745ADE5B7

P50

Q34725141-12D59EAC-E6B9-465F-9848-13DFFEDCCE1E

P577

Q34725141-6484279D-F026-4DC0-9576-D84AE1D34826

P5875

Q34725141-A05B7F1C-B8B0-4A53-9351-A954FE2D6561

P698

Q34725141-56F8CC63-AF1E-4598-9E1B-16F5489967DD

P921

Q34725141-5154B5ED-DCD8-4329-BD35-999D10DC5CAA

P356

BLOOD-2007-10-117010

P1433

P1476

Ki-67 predicts outcome in adva ...... ow Grade Lymphoma Study Group.

@en

P2093

European Mantle Cell Lymphoma Network and the German Low Grade Lymphoma Study Group

http://www.w3.org/2001/XMLSchema#string

Eva Hoster

http://www.w3.org/2001/XMLSchema#string

German Ott

http://www.w3.org/2001/XMLSchema#string

Heinz Wolfram Bernd

http://www.w3.org/2001/XMLSchema#string

Martin Dreyling

http://www.w3.org/2001/XMLSchema#string

Martin Leo Hansmann

http://www.w3.org/2001/XMLSchema#string

Michael Unterhalt

http://www.w3.org/2001/XMLSchema#string

Olaf Determann

http://www.w3.org/2001/XMLSchema#string

Thomas E F Barth

http://www.w3.org/2001/XMLSchema#string

Wolfgang Hiddemann

http://www.w3.org/2001/XMLSchema#string

P304

2385-2387

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2007-10-117010

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Christoph Loddenkemper

P577

2007-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5770378

http://www.w3.org/2001/XMLSchema#string

P698

18077791

http://www.w3.org/2001/XMLSchema#string

P921